Evaluation of sodium cromoglycate and medrysone in the management of atopic keratoconjunctivitis: a double masked clinical study.
The efficacy of topical sodium cromoglycate and medrysone was evaluated in 38 patients suffering from atopic keratoconjunctivitis. It was found that medrysone (1%) significantly improved the symptoms of itching, watering, photophobia and hyperaemia, while sodium cromoglycate (2%) was found to be ineffective. Tear prostaglandin E2 and histamine levels did not decrease significantly after sodium cromoglycate therapy. The findings of the present study reveal that sodium cromoglycate has no significant role in the management of atopic keratoconjunctivitis.
D000293:Adolescent; D000328:Adult; D002648:Child; D004205:Cromolyn Sodium / Q000627:therapeutic use*; D015232:Dinoprostone; D004311:Double-Blind Method; D004341:Drug Evaluation; D005260:Female; D006632:Histamine / Q000378:metabolism; D006801:Humans; D007637:Keratoconjunctivitis / Q000188:drug therapy* / Q000378:metabolism; D008297:Male; D011282:Pregnenediones / Q000627:therapeutic use*; D011458:Prostaglandins E / Q000378:metabolism; D013666:Tears / Q000378:metabolism
D011282:Pregnenediones; D011458:Prostaglandins E; D006632:Histamine; C100283:medrysone; D015232:Dinoprostone; D004205:Cromolyn Sodium